Pilot Study Of Safety And Feasibility Of GI-4000, An Inactivated Recombinant Saccharomyces Cerevisiae Expressing Mutant Ras Protein Combined With Adoptive Transfer And Chemoradiation in Locally Advanced Pancreatic Cancer.

Trial Profile

Pilot Study Of Safety And Feasibility Of GI-4000, An Inactivated Recombinant Saccharomyces Cerevisiae Expressing Mutant Ras Protein Combined With Adoptive Transfer And Chemoradiation in Locally Advanced Pancreatic Cancer.

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 23 Aug 2016

At a glance

  • Drugs GI 4000 (Primary) ; Antineoplastics
  • Indications Pancreatic cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 16 Oct 2009 Planned end date changed from 1 Jan 2010 to 1 Oct 2009 as reported by ClinicalTrials.gov.
    • 08 Aug 2009 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 11 Feb 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top